Trial Profile
BIOTRONIK - SaFety and Performance Registry for an Allcomers Patient Population With the SiroLimus Eluting Orsiro Stent Within Daily Clinical Practice in Small Vessels - Portugal Registry
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms BIOFLOW-SV
- Sponsors BIOTRONIK
- 14 Feb 2024 Status changed from recruiting to discontinued (Problem with enrollment due to Covid-19).
- 16 Jul 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 16 Jul 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.